Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC–MS/MS: Application to a pharmacokinetic study

Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors

Evan Parganas, Demin Wang, Dimitrios J. Stravopodis et al. · Cell · 1998 · 1.2K citations · Full text

Inflammation, Cytokine, Signal Transduction +10

Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis

Hans Neubauer, Ana Cumano, Mathias Müller et al. · Cell · 1998 · 907 citations · Full text

Developmental Biology, Cell Division, Receptor Tyrosine Kinase +5

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Alfonso Quintás‐Cardama, Kris Vaddi, Phillip Liu et al. · Blood · 2010 · 813 citations

Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis

RJ Jacobson, A Salo, PJ Fialkow · Blood · 1978 · 490 citations · Full text

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry

Amina Haouala, Boris Zanolari, Bertrand Rochat et al. · Journal of Chromatography B · 2009 · 202 citations

Therapeutic Drug Monitoring, Medicinal Chemistry, Medicine +10